Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIOMATIC-SSP: Milvexian for Secondary Stroke Prevention
NCT03766581Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 2 trial of milvexian in ischemic stroke, Transient Ischemic Attack (TIA), sponsored by Bristol Myers Squibb. Started Jan 2019; status: completed.
02
Drugs
milvexian
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT03766581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766581.